Sinovant is backed by Roivant Sciences and CITIC Private Equity. Leveraging CITIC PE’s strategic insights into healthcare markets in Greater China and Asia and Roivant’s global business development network and drug development capabilities, Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.